Next-gen sequencing, mass spec to be used in PTSD consortium work

08/13/2013 | GenomeWeb Daily News (free registration)

The STRONG STAR Consortium to Alleviate PTSD, also known as the STRONG STAR-CAP, will use next-generation sequencing to look at structural contributors in diagnosing and treating PTSD, as well as mass spectrometry to discover protein biomarkers that could help predict PTSD risk. The consortium, led by the University of Texas Health Science Center in San Antonio, is receiving a $45 million grant from the Defense Department and Department of Veterans Affairs to support the research.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA